SCHEMBL5118402

SCHEMBL5118402

O=C1Nc2cccc(Cl)c2C(C2CCCC2)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PBRM1 Q86U86 5/20 0.38
▸ SMARCA2 P51531 2/20 0.38
▸ SMARCA4 P51532 2/20 0.38
▸ HTR5A P47898 5/20 0.37
▸ HTR1A P08908 4/20 0.37
▸ HTR2C P28335 4/20 0.37
▸ HTR7 P34969 4/20 0.37
▸ HTR1D P28221 3/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR3A P46098 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ HRH1 P35367 1/20 0.37
▸ PDE7A Q13946 1/20 0.37
▸ TP53 P04637 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ CES1 P23141 1/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5124908 0.78 NR3C1 (0.30) —
SCHEMBL5111570 0.76 HTR5A (0.46) PBRM1SMARCA2SMARCA4HTR5AHTR1A
SCHEMBL5119433 0.73 HTR5A (0.47) PBRM1SMARCA2SMARCA4HTR5AHTR1A
SCHEMBL31402353 0.71 CES1 (0.37) PBRM1SMARCA2SMARCA4HTR5AHTR1A
SCHEMBL5126253 0.70 PGR (0.43) —
SCHEMBL5117969 0.70 PBRM1 (0.41) PBRM1SMARCA2SMARCA4HTR5AHTR1A
SCHEMBL11245221 0.68 MAPT (0.42) GAA
SCHEMBL11039038 0.67 CA2 (0.55) PBRM1SMARCA2SMARCA4HTR5AHTR1A
SCHEMBL24740178 0.66 HTR5A (0.45) PBRM1SMARCA2SMARCA4HTR5AHTR1A
SCHEMBL24019656 0.66 HTR5A (0.45) PBRM1SMARCA2SMARCA4HTR5AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442696-B2 Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses LIGAND PHARMACEUTICALS, INC. (US) 2008-10-28 — — US disclosed
US-20070197520-A1 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES LIGAND PHARMACEUTICALS INC. 2007-08-23 — — US disclosed
WO-2006010142-A2 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE LIGAND PHARMACEUTICALS, INC. (US) 2006-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197520-A1 MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES NR3C2, MC2R, NR3C1 PBRM1 2599/4885SMARCA2 3346/4885SMARCA4 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback